<DOC>
	<DOCNO>NCT00784836</DOCNO>
	<brief_summary>The primary objective study evaluate immunogenicity Avonex速 ( interferon beta-1a ) 30 mcg administer subcutaneously ( SC ) interferon-na誰ve participant relapse multiple sclerosis . The secondary objective study evaluate safety tolerability Avonex速 30 mcg administer SC interferon-na誰ve subject relapse MS .</brief_summary>
	<brief_title>Immunogenicity Safety Subcutaneously-administered Avonex ( Interferon Beta-1a ) Multiple Sclerosis ( MS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Male female age 18 60yearsold , inclusive , time informed consent . Must diagnosis relapse MS. Must screen Expanded Disability Status Scale ( EDSS ) score 0 6.0 , inclusive . All male subject female participant childbearing potential must practice effective contraception study willing able continue contraception 30 day last study dose Avonex . History severe allergic anaphylactic reaction . Diagnosed Primary progressive , secondary progressive , progressive relapsing MS . Known allergy component Avonex formulation . History clinically significant ( determined investigator ) cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric renal , major disease . Subjects history malignant disease , include solid tumor hematologic malignancy . History seizure disorder unexplained blackout OR history seizure within 3 month prior Day 1 . History suicidal ideation within 3 month prior Day 1 episode severe depression within 3 month prior Day 1 . Severe depression define episode depression require hospitalization , initiation antidepressant therapy , increase dose exist regimen antidepressant therapy . Clinically significant abnormal electrocardiogram ( ECG ) value determine investigator . Known history , positive test result , human immunodeficiency virus ( HIV ) . Known history , positive test result hepatitis C virus . Abnormal screen blood test exceed limit define : 1 . Alanine transaminase/serum glutamate pyruvate transaminase ( ALT/SGPT ) great 2 time upper limit normal aspartate transaminase/serum glutamic oxaloacetic transaminase bilirubin . 2 . Total white blood cell count ( WBC ) &lt; 3700 cells/mm 3 . Platelet count &lt; 150,000 cells/mm 4 . Hemoglobin &lt; 10 g/dL female subject ; &lt; 11 g/dL male subject 5 . Serum creatinine &gt; upper limit normal ( ULN ) 6 . Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) &gt; 1.2*ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Multiple Sclerosis - Relapsing</keyword>
</DOC>